Navigation Links
Asymmetrex’s New Patent Issued for Counting and Evaluating Therapeutic Adult Tissue Stem Cells Also Supports Company’s New Stem Cell Production Services

Any expert in stem cell research or stem cell medicine knows well the major unmet need that has compromised these disciplines for more than half a century. Despite their essential roles in human health and regenerative medicine, adult tissue stem cells cannot be counted. It is widely known that molecular tags developed for this purpose also tag other, more abundant, non-stem tissue cells (See 2017 Cell & Gene Exchange video). But many non-experts are surprised when they learn that stem cell science and stem cell medicine are held back because of not knowing the number of stem cells in experiments or the dose and quality of therapeutic tissue stem cells in treatments. And the lack of a way to quantify tissue stem cells means that detection of drug candidates or environmental agents that impact them is prohibitively complex and expensive.

The new patent is the basis for Asymmetrex’s contract research service, the AlphaSTEM Test Service. In addition to the company’s website, the contract service is listed on Science Exchange and The Scientist’s Suppliers sites as a certified provider and featured supplier, respectively. The new technology uses simple total cell count data from serially passaged cell cultures to decipher, for the first time, the specific number and functions of tissue stem cells in complex preparations like experimental or treatment samples. The desired data is extracted with proprietary computer simulation software developed with partner AlphaSTAR Corporation.

Asymmetrex offers its new contract service to diverse users in tissue stem cell research and medicine. Several national and international academic labs are now beta-testing the counting technology for quantifying stem cells in tissues of different animal species. Centers and clinics providing either approved or experimental therapies can use the service to determine the dose and quality of stem cells in their treatments. Asymmetrex estimates that many U.S. pharmaceutical companies would save hundreds of millions of dollars in unnecessary animal studies and clinical trials, if they employed the AlphaSTEM Test service for early screening for stem cell-toxic drug candidates. In later more expensive evaluations, these are the common drug candidates that cause chronic organ failure. In much the same way that the service can identify stem cell-toxic agents, it can also identify beneficial compounds that promote stem cell health or production.

A more recent projection of the technology’s application indicates another exciting prospect for accelerating progress in stem cell therapies. Production of tissue stem cells of sufficient number and quality to support stem cell transplantation treatments is another well-known major technical challenge in stem cell medicine. Not only can the AlphaSTEM technology provide monitoring of stem cell number during production processes, but it can also be used to design more efficient and effective production. For bone marrow-derived mesenchymal stem cells, company founder and director James Sherley, M.D., Ph.D. states, “We can provide stem cell producer companies simple methods for producing twice as many stem cells, in half the time, at 5% or less the cost.” So, both cell therapy developers and their stem cell suppliers should take great interest in the new services and their advantages.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the quality and dose of tissue stem cell preparations (the “AlphaSTEM Test”) for use in stem cell transplantation therapies and in pre-clinical assays for drug safety.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Asymmetrex’s Head Will Lead Discussion on Supplying Private Stem Cell Clinics at the 6th Annual Clinical Trial Supply New England 2017 Conference in Boston
2. Asymmetrex’s Crowdsourcing Campaign For Evaluating A First Biomarker for Counting Adult Tissue Stem Cells Is Gaining Momentum
3. CardioWise™ Acquires Worldwide Rights to New Cardiac CT Analysis, Patents, Software and Technology Through License Agreement with Johns Hopkins Technology Ventures
4. G-CON Manufacturing Announces that it has Received its Second and Third Notices of Allowance for Patents on its Modular, Pre-Fabricated Mobile Clean Room System
5. Xylogenics Announces Latest Advancements in Patented GX-1 Yeast Technology
6. DuPont Pioneer Secures Exclusive Rights to ERS Genomics’ CRISPR-Cas Patent Portfolio for Agriculture
7. Kibow Biotech Inc. (Buzz of Bio Winner, 2014) Receives US Patent for Gout/Hyperuricemia Product Formulation Based on Modulation of the Gut Microbiome With Probiotics and Prebiotics
8. Zansors Secures Issued Patent for Heart Monitoring Device
9. Nanomedical Diagnostics Issued Key Patent for AGILE R100, a Graphene Biosensor for Drug Discovery
10. DuPont Pioneer and Vilnius University Announce CRISPR-Cas Patent Grant
11. Bactana Animal Health Receives Patent Notice of Allowance
Post Your Comments:
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The ... medical marijuana products targeting the needs of consumers who are incorporating medical marijuana ... place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The ...
Breaking Biology Technology:
(Date:5/16/2017)...  Veratad Technologies, LLC ( ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):